All In Biotech

Drug Trial Radar · NCT01519674

Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin

A 24 Week Randomised, Open Label, 3 Parallel-group Comparison of Once and Twice Daily Biphasic Insulin Aspart (BIAsp) 30 Plus Sitagliptin and Twice Daily BIAsp 30, All in Combination With Metformin in Insulin naïve Type 2 Diabetic Subjects Inadequately Controlled on Sitagliptin and Metformin

Last checked: Nov 20, 2026Latest source record: Feb 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 582 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

582

Actual

Start

Jun 2012

Primary completion

Oct 2013

Study completion Oct 2013

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Asia, Europe, Oceania and South America. The aim of this clinical trial is to generate data demonstrating how to intensify diabetes treatment using BIAsp 30 (biphasic insulin aspart 30) by adding or substituting BIAsp 30 to sitagliptin in various regimens for type 2 patients inadequately controlled on sitagliptin and metformin (with or without other oral anti-diabetic drugs (OADs)). The trial is conducted as a phase 4 trial in the majority of the participating countries. However, in some countries the trial is conducted as phase 3b.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • biphasic insulin aspart 30Drug

    BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.

  • biphasic insulin aspart 30Drug

    BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.

  • sitagliptinDrug

    Subjects will continue on their pre-trial sitagliptin treatment.

  • metforminDrug

    Subjects will continue on their pre-trial metformin treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)Time frame: Week 0 to Week 24

Locations

69 sites in 10 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Buenos Aires, Argentina

  • Novo Nordisk Investigational Site

    Buenos Aires, Argentina

  • Novo Nordisk Investigational Site

    Caba, Argentina

  • Novo Nordisk Investigational Site

    Caba, Argentina

  • Novo Nordisk Investigational Site

    Mar del Plata, Argentina

  • Novo Nordisk Investigational Site

    Morón, Argentina

  • Novo Nordisk Investigational Site

    Broadmeadow, New South Wales, Australia

  • Novo Nordisk Investigational Site

    Coffs Harbour, New South Wales, Australia

  • Novo Nordisk Investigational Site

    Brasília, Brazil

  • Novo Nordisk Investigational Site

    Curitiba, Brazil

  • Novo Nordisk Investigational Site

    Fortaleza, Brazil

  • Novo Nordisk Investigational Site

    Porto Alegre, Brazil

  • Novo Nordisk Investigational Site

    São Paulo, São Paulo, Brazil

  • Novo Nordisk Investigational Site

    Alexandroupoli, Greece

  • Novo Nordisk Investigational Site

    Athens, Greece

  • Novo Nordisk Investigational Site

    Athens, Greece

  • Novo Nordisk Investigational Site

    Thessaloniki, Greece

  • Novo Nordisk Investigational Site

    Thessaloniki, Greece

  • Novo Nordisk Investigational Site

    Thessaloniki, Greece

  • Novo Nordisk Investigational Site

    Hyderabad, Andhra Pradesh, India

  • Novo Nordisk Investigational Site

    Hyderabad, Andhra Pradesh, India

  • Novo Nordisk Investigational Site

    Hyderabad, Andhra Pradesh, India

  • Novo Nordisk Investigational Site

    Visakhapatnam, Andhra Pradesh, India

  • Novo Nordisk Investigational Site

    Ahmedabad, Gujarat, India

  • Novo Nordisk Investigational Site

    Ahmedabad, Gujarat, India

  • Novo Nordisk Investigational Site

    Bangalore, Karnataka, India

  • Novo Nordisk Investigational Site

    Bangalore, Karnataka, India

  • Novo Nordisk Investigational Site

    Bangalore, Karnataka, India

  • Novo Nordisk Investigational Site

    Bangalore, Karnataka, India

  • Novo Nordisk Investigational Site

    Calicut, Kerala, India

  • Novo Nordisk Investigational Site

    Trivandrum, Kerala, India

  • Novo Nordisk Investigational Site

    Nagpur, Maharashtra, India

  • Novo Nordisk Investigational Site

    New Delhi, New Delhi, India

  • Novo Nordisk Investigational Site

    Amritsar, Punjab, India

  • Novo Nordisk Investigational Site

    Chennai, Tamil Nadu, India

  • Novo Nordisk Investigational Site

    Chennai, Tamil Nadu, India

  • Novo Nordisk Investigational Site

    Chennai, Tamil Nadu, India

  • Novo Nordisk Investigational Site

    Coimbatore, Tamil Nadu, India

  • Novo Nordisk Investigational Site

    Trichy, Tamil Nadu, India

  • Novo Nordisk Investigational Site

    Kanpur, Uttar Pradesh, India

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.